Quick Summary:
In a rapidly expanding healthcare sector, understanding the dynamics of the Biotherapeutics Cell Line Development Market is crucial for any forward-thinking business decision maker. This detailed report, projected to see a global scale valuation reaching up to US$135.2 million by 2030, provides in-depth insights into this thriving market that could equip your company with the knowledge it needs to stay competitive in your industry, and capitalize on potential growth areas.
The market's financial potential is significant, with the U.S alone expected to account for $25.2 million in 2022, while China's market is predicted to increase at a CAGR of 5.6% until 2030. Highlighting established and emerging markets, this report offers an essential comparative analysis. You will gain access to exclusive data on competitive companies, their market shares, and their geographical presence, enabling your business to strategize effectively, capitalize on new trends, and navigate potential challenges in the global Biotherapeutics Cell Line Development sector.
Global Biotherapeutics Cell Line Development Market to Reach $135.2 Million by 2030
The global market for Biotherapeutics Cell Line Development estimated at US$83.4 Million in the year 2022, is projected to reach a revised size of US$135.2 Million by 2030, growing at a CAGR of 6.2% over the analysis period 2022-2030. Transfection & Selection, one of the segments analyzed in the report, is projected to record 7.9% CAGR and reach US$28.9 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Single Cell Cloning segment is readjusted to a revised 5.8% CAGR for the next 8-year period.
The U.S. Market is Estimated at $25.2 Million, While China is Forecast to Grow at 5.6% CAGR
The Biotherapeutics Cell Line Development market in the U.S. is estimated at US$25.2 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$23 Million by the year 2030 trailing a CAGR of 5.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6% and 4.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.Select Competitors (Total 11 Featured) -
- AGC Biologics
- Beckman Coulter, Inc.
- Becton, Dickinson & Company
- Boehringer Ingelheim International GmbH
- Catalent, Inc.
- EMD Millipore Corporation
- Lonza Group Ltd.
- MilliporeSigma
- ProBioGen AG
- Selexis SA
- Sony Biotechnology Inc.
- Sysmex Corporation
- Thermo Fisher Scientific, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Biotherapeutics Cell Line Development?
What is the growth rate of the Global Market for Biotherapeutics Cell Line Development?
What is the forecasted size of the Global Market for Biotherapeutics Cell Line Development?
Who are the key companies in the Global Market for Biotherapeutics Cell Line Development?
| Report Attribute | Details |
|---|---|
| No. of Pages | 179 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 83.4 Million |
| Forecasted Market Value ( USD | $ 135.2 Million |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- AGC Biologics
- Beckman Coulter, Inc.
- Becton, Dickinson & Company
- Boehringer Ingelheim International GmbH
- Catalent, Inc.
- EMD Millipore Corporation
- Lonza Group Ltd.
- MilliporeSigma
- ProBioGen AG
- Selexis SA
- Sony Biotechnology Inc.
- Sysmex Corporation
- Thermo Fisher Scientific, Inc.
